InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.270 0.01 (0.44%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$847 Clarity Presentation for Bell Potter Healthcare conference 10 Nov 2021 10:53AM $1.040 $2.270 risen by 118.27%
$847 Dosimetry Recruitment of theranostic prostate trial complete 10 Nov 2021 8:51AM $1.030 $2.270 risen by 120.39%
$847 Appendix 4C Cash Flow Report 27 Oct 2021 9:48AM $1.130 $2.270 risen by 100.88%
$847 Notice of Annual General Meeting/Proxy Form 22 Oct 2021 2:09PM $1.130 $2.270 risen by 100.88%
$847 Annual Report to shareholders 22 Oct 2021 2:08PM $1.130 $2.270 risen by 100.88%
$847 Recruitment closed on C-BOBCAT SAR-Bombesin trial 19 Oct 2021 9:59AM $1.100 $2.270 risen by 106.36%
$847 Manufacturing agreement for Clarity's US clinical trials 30 Sep 2021 10:46AM $1.265 $2.270 risen by 79.45%
$847 Notice of Annual General Meeting 29 Sep 2021 3:44PM $1.210 $2.270 risen by 87.60%
$847 Clarity joins the CORAR 22 Sep 2021 10:28AM $1.280 $2.270 risen by 77.34%
$847 Release of securities from escrow 21 Sep 2021 9:27AM $1.340 $2.270 risen by 69.40%
$847 Becoming a substantial holder - GenesisCare 2 Sep 2021 9:04AM $1.400 $2.270 risen by 62.14%
$847 Company Briefing 1 Sep 2021 9:59AM $1.430 $2.270 risen by 58.74%
$847 Becoming a substantial holder - Taylor 30 Aug 2021 2:02PM $1.485 $2.270 risen by 52.86%
$847 Becoming a substantial holder - Morgan 30 Aug 2021 12:42PM $1.485 $2.270 risen by 52.86%
$847 Becoming a substantial holder - Cabbit Pty Ltd 30 Aug 2021 12:16PM $1.498 $2.270 risen by 51.59%
$847 Becoming a substantial holder - Harris 30 Aug 2021 10:45AM $1.505 $2.270 risen by 50.83%
$847 Becoming a substantial holder - TM Ventures 30 Aug 2021 10:43AM $1.505 $2.270 risen by 50.83%
$847 App 3X Initial Director's Interest Notice - all directors 26 Aug 2021 5:49PM $1.400 $2.270 risen by 62.14%
$847 App 4E Preliminary Final Report 30 June 2021 25 Aug 2021 6:30PM n/a $2.270 n/a
$847 First patient treated in theranostic prostate cancer trial 25 Aug 2021 11:05AM n/a $2.270 n/a
$847 Clarity Pharmaceuticals lists on the ASX 25 Aug 2021 11:05AM n/a $2.270 n/a
$847 Pre-Quotation Disclosure Statement 24 Aug 2021 10:44AM n/a $2.270 n/a
$847 Top 20 Shareholders 24 Aug 2021 10:42AM n/a $2.270 n/a
$847 Distribution Schedule 24 Aug 2021 10:41AM n/a $2.270 n/a
$847 Corporate Governance Statement 24 Aug 2021 10:40AM n/a $2.270 n/a

476 - 500 of 511 results

Page 20 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.